Actively Recruiting
A Phase 2 Multicenter Study Evaluating Luspatercept for Anemia Due to Chronic Kidney Disease
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-10-13
30
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating luspatercept for its ability to improve hemoglobin levels in people with anemia caused by chronic kidney disease CKD. This phase 2 study aims to test if luspatercept is a safe treatment option with only mild or few side effects in participants with this condition. Participants will receive luspatercept through subcutaneous injections once every three weeks. The study follows a single-group design, where all enrolled participants receive the same treatment. The primary outcome is to measure hemoglobin improvement within 12 weeks, with additional measurements taken up to week 28. During the study, participants will have their hemoglobin levels monitored to assess treatment effects. Eligibility requires specific laboratory values and stable kidney function. Safety evaluations and assessments will be conducted throughout the study period, which lasts until July 2029. Participants will be closely observed to track any side effects and treatment responses.
CONDITIONS
Brief Title
A Study of Luspatercept in People With Anemia
Research Team
J
Jodi Mones, MD
J
Jeffrey Zwicker, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
